Ionis Pharmaceuticals Will Present New Three-year Data From The Phase 2 Open-label Extension Study As Well As Additional Results From The Pivotal Phase 3 OASIS and OASISplus Studies Of Donidalorsen For Hereditary Angioedema At The 2024 American...
Ionis Pharmaceuticals Will Present New Three-year Data From The Phase 2 Open-label Extension Study As Well As Additional Results From The Pivotal Phase 3 OASIS and OASISplus Studies Of Donidalorsen For Hereditary Angioedema At The 2024 American...
ionis pharmaceuticals將在2024年的美國...大會上發佈來自2期開放標籤延長研究的新三年數據，以及Donidalorsen用於家族性血管性水腫的關鍵3期OASIS和OASISplus研究的額外結果。
Ionis Pharmaceuticals Will Present New Three-year Data From The Phase 2 Open-label Extension Study As Well As Additional Results From The Pivotal Phase 3 OASIS and OASISplus Studies Of Donidalorsen For Hereditary Angioedema At The 2024 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting
ionis pharmaceuticals將在2024年美國變應教育學院年度科學會議上發佈新三年數據，這些數據來自2期開放標籤擴展研究及Donidalorsen用於遺傳性血管性水腫的關鍵第三階段OASIS和OASISplus研究的額外結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。